See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Tariffs
Trade War
Donald Trump
Artificial Intelligence
Social Media
Trade
Natural Disasters
Stock Markets
Baseball
European Union
Education
US Economy
Published • loading... • Updated

F-star management takes company private, two years after $161M cash exit to Sino's invoX

Summary by Endpoints News
UK antibody developer F-star Therapeutics has become a private, independent biotech. The surprise move — announced via F-star's LinkedIn page on Thursday — comes two years after a drawn-out $161 million M&A exit ...
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Endpoints NewsEndpoints News

F-star management takes company private, two years after $161M cash exit to Sino's invoX

UK antibody developer F-star Therapeutics has become a private, independent biotech. The surprise move — announced via F-star's LinkedIn page on Thursday — comes two years after a drawn-out $161 million M&A exit ...

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Endpoints News broke the news in on Friday, April 4, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

LinkedIn

LinkedIn

United Kingdom

United Kingdom

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal